RESUMO
OBJECTIVE: MSB11022 is a biosimilar of adalimumab that has been shown comparable bioequivalence, safety, tolerability, and immunogenicity profiles to the reference adalimumab in healthy volunteers or in patients with psoriasis or rheumatoid arthritis (RA). This is the first study conducted under clinical practice conditions evaluating the switch from reference adalimumab to MSB11022 in patients with RA. METHODS: Retrospective and multicenter study with data from the medical records of patients with RA who switched from reference adalimumab or another biosimilar to MSB11022 and maintained this treatment for at least 6 months. Information registered comes from baseline visit, the moment of the switch, and the follow-up visits. RESULTS: Data from 86 patients were evaluated (median age 63.5 years, 75.6% female, 44.2% had erosive RA). Only 3.5% of the patients received biologic therapy prior to adalimumab. At baseline, median DAS28-CRP was 1.77 (80.2% in remission and 96.5% with low disease activity) and median CDAI was 4.00 (44.2% in remission and 90.7% with low disease activity). After a median follow-up of 8 months, median DAS28-CRP was 1.87 (86.0% in remission and 94.2% with low disease activity) and median CDAI was 4.00 (38.5% in remission and 95.3% with low disease activity). Only three patients experienced pain, swelling, and stinging at the injection site or a locally extensive hematoma in the area of administration. CONCLUSIONS: Adalimumab biosimilar MSB11022 maintained the efficacy benefits provided by previous adalimumab treatments with a safety profile in line with that already described for other biosimilars.
RESUMO
OBJETIVOS: conocer la efectividad del modelo de atención centrada en la persona en la rehabilitación visual. MÉTODO: se seleccionaron artículos publicados entre 2010 y 2019, recogidos en PUBMED y Web of Science. Se incluyeron aquellos dedicados a la terapia ocupacional y rehabilitación visual de personas con discapacidad visual desde un enfoque de atención centrado en la persona. Finalmente se incluyeron 14 artículos para esta revisión. RESULTADOS: de la búsqueda en PubMed se obtuvieron un total de 490 artículos y de Web of science 40, alcanzando un total de 530 artículos. Después de realizar la lectura del título, se seleccionaron 126 artículos. Tras la lectura de los resúmenes y/o el contenido completo, se excluyeron 112 por no cumplir los objetivos del estudio; resultando elegidos 13 artículos. Las diferentes investigaciones recopiladas justifican que la rehabilitación visual y la terapia ocupacional basadas en el modelo de atención centrada en la persona contribuyen a mejorar la calidad de vida de las personas con baja visión y su autonomía personal. CONCLUSIÓN: son necesarias más investigaciones que evidencien cómo la terapia ocupacional desde una atención centrada en la persona produce resultados positivos en la rehabilitación de personas con baja visión
OBJECTIVE: To know the effectiveness of the person-centered care model in visual rehabilitation. METHOD: Articles published between 2010 and 2019, collected in PUBMED and Web of Science, were selected. Those dedicated to occupational therapy and visual rehabilitation of people with visual disabilities from a person-centered care approach were included. Finally 14 articles were included for this review. RESULTS: A total of 490 articles were obtained from the PubMed search and 40 from Web of science, reaching a total of 530 articles. After reading the title, 126 articles were selected. After reading the abstracts and / or the full content, 112 were excluded because they did not meet the study objectives; resulting in 13 articles chosen. The different studies collected justify that visual rehabilitation and occupational therapy based on the person-centered care model contribute to improving the quality of life of people with low vision and their personal autonomy. CONCLUSION: More research is needed to show how occupational therapy from a person-centered care produces positive results in the rehabilitation of people with low vision
